Rodman & Renshaw Upgrades NxStage Medical

Rodman & Renshaw upgraded its NxStage

rating to Market Perform in a research report published today. In the report, Rodman & Renshaw states, "We are upgrading our rating to a Market Perform. The stock is close to our PT and given the risks we see on the horizon, is fairly valued at the current levels." Shares of NxStage closed today at $19.27, up 13.62% from Tuesday's market close.